Technical Analysis for REPL - Replimune Group, Inc.

Grade Last Price % Change Price Change
B 12.24 -2.08% -0.26
REPL closed up 0.48 percent on Monday, November 11, 2024, on 58 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bulls were able to push the stock to a new 52-week high.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Flat

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup -2.08%
NR7 Range Contraction -2.08%
New 52 Week High Strength -2.08%
Gapped Up Strength -2.08%
Upper Bollinger Band Touch Strength -2.08%
Inside Day Range Contraction -1.61%
Bearish Engulfing Bearish 0.25%
Stochastic Sell Signal Bearish 0.25%
Upper Bollinger Band Walk Strength 0.25%
Outside Day Range Expansion 0.25%

   Recent Intraday Alerts

Alert Time
Fell Below 10 DMA about 1 hour ago
20 DMA Support about 5 hours ago
10 DMA Support about 5 hours ago
Down 5% about 5 hours ago
Down 3% about 5 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP, RP2, and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate, RP1, in approximately 150 patients with a range of solid tumors.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Cancer Treatment Virotherapy Immunotherapy Products Oncolytic Virus Experimental Cancer Treatments Transgene Sa Akseli Hemminki Rp1

Is REPL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 12.97
52 Week Low 4.92
Average Volume 655,914
200-Day Moving Average 8.97
50-Day Moving Average 11.38
20-Day Moving Average 11.89
10-Day Moving Average 12.19
Average True Range 0.63
RSI (14) 59.35
ADX 16.88
+DI 19.42
-DI 14.62
Chandelier Exit (Long, 3 ATRs) 11.08
Chandelier Exit (Short, 3 ATRs) 11.83
Upper Bollinger Bands 12.85
Lower Bollinger Band 10.93
Percent B (%b) 0.82
BandWidth 16.08
MACD Line 0.31
MACD Signal Line 0.28
MACD Histogram 0.0318
Fundamentals Value
Market Cap 767.35 Million
Num Shares 61.4 Million
EPS -3.16
Price-to-Earnings (P/E) Ratio -3.96
Price-to-Sales 0.00
Price-to-Book 1.13
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.28
Resistance 3 (R3) 13.35 13.16 13.15
Resistance 2 (R2) 13.16 12.96 13.13 13.11
Resistance 1 (R1) 12.83 12.84 12.74 12.76 13.06
Pivot Point 12.64 12.64 12.59 12.61 12.64
Support 1 (S1) 12.31 12.44 12.22 12.24 11.94
Support 2 (S2) 12.12 12.32 12.09 11.89
Support 3 (S3) 11.79 12.12 11.85
Support 4 (S4) 11.72